Invion commences clinical trial for INV043

Invion (ASX:IVX) has commenced dosing the first patient in its Phase I/II clinical trial for non-melanoma skin cancer using its lead drug candidate, INV043. The trial, conducted in Queensland, Australia, will assess the safety and efficacy of INV043, a photosensitiser for Photodynamic Therapy.

Overview of INV043 clinical trial and future outlook

Invion Limited has launched a Phase I/II clinical trial for its drug candidate INV043, aimed at treating non-melanoma skin cancer. The trial, held in Queensland, will evaluate the safety and efficacy of INV043, exploring its advantages in minimizing scarring and pain compared to traditional treatments. The study, which starts with 18 patients, is adaptive and may expand its focus. The trial is expected to contribute to future studies, including a Phase II trial for anogenital cancer. INV043 is part of Invion’s Photosoft technology, promising less invasive cancer treatments with fewer side effects. Invion is committed to developing innovative therapies and holds exclusive rights to Photosoft technology in multiple regions.

Executive insights on INV043 trial

Thian Chew, Executive Chair and CEO, highlighted the significance of the trial in advancing Photosoft technology as a viable alternative to current NMSC treatments and its potential applicability across multiple cancer types.